Drug Discovery & DDS– category –
-
Insilico Medicine’s AI-Designed Drug Rentosertib Shows Early Signs of Biological Age Reversal, Enters Phase III for Idiopathic Pulmonary Fibrosis
Inc.com USA Overview Insilico Medicine's AI-generated small molecule, rentosertib, has demonstrated early signs of reducing six protein-based biological age markers by an average of 10.3% in a 12-week clinical trial. This breakthrough ma... -
Drug Discovery & DDS Weekly Report September 6, 2026
▼ ▼ ▼ If the infographic makes you want to read the full report, please click the download button below. ▼ ▼ ▼ 📄 Weekly Report September 06, 2026 (PDF) — Download Weekly Report September 06, 2026 (PDF) — DownloadDownload 🎙 Podcast Septe... -
AI-Designed Drug Makes Human Debut: BigHat Biosciences Begins Clinical Trial for Gastric Cancer ADC
BigHat Biosciences USA Overview BigHat Biosciences has initiated a Phase 1 clinical trial for BHB810, a novel CDH17-targeted VHH-Fc antibody-drug conjugate (ADC) designed using its AI-powered antibody design platform. Developed for gastr... -
Protein Accumulation Mechanism is Key to PROTAC Efficacy, Unlocking New Strategies for Refractory Cancers
News-Medical UK Overview Researchers have discovered that the mechanism by which cancer-driving proteins accumulate within tumors significantly influences the efficacy of PROTAC drugs. The study demonstrated that PROTACs are more effecti... -
The Multispecific Antibody Revolution: Reshaping CDMOs for Next-Gen Biologics
BioSpace USA Overview The rapid advancement of multispecific antibody therapeutics is fundamentally transforming the service delivery models and development architectures of Contract Development and Manufacturing Organizations (CDMOs). T... -
UBC Bolsters AI-Driven Drug Discovery and Protein Design with New Research Chairs
UBC Medicine Canada Overview The University of British Columbia's Faculty of Medicine has appointed three world-renowned scientists as Eddie Goldenberg Research Chairs to accelerate breakthroughs in AI-driven protein design, drug deliver... -
Genentech and DualityBio Forge $1B+ Partnership to Accelerate Novel ADC Payloads, Combat Resistance
Fierce Biotech USA Overview Roche's Genentech has announced a significant collaboration with DualityBio, a deal potentially exceeding $1 billion, aimed at developing next-generation Antibody-Drug Conjugates (ADCs). This partnership will ... -
Polymeric Nanoparticles Unlock New Frontiers in Drug Delivery, Gene Therapy, and Medical Imaging
Nanbiosis Spain Overview Polymeric nanoparticles are emerging as a highly versatile and promising platform in nanomedicine, poised to revolutionize areas such as drug delivery, gene therapy, and medical imaging. Their customizable nature... -
Logic-Gated Bispecific ADCs Break Toxicity Barrier, Unleash Thousands of New Cancer Targets
Drug Discovery News USA Overview A novel logic-gated platform for bispecific antibody-drug conjugates (bsADCs) shows promise in unlocking thousands of previously inaccessible cancer targets for therapeutic development. By simultaneously ... -
BRD4-Targeting PROTAC Nanoassemblies Dramatically Enhance FLASH Radiotherapy, Achieving Robust Tumor Suppression
PMC USA Overview New research reveals that BRD4-targeting PROTAC nanoassemblies (APF) significantly amplify the anti-tumor efficacy of ultra-high dose rate FLASH radiotherapy (FLASH-RT). By efficiently delivering the BRD4 degrader ARV-77...
